Actavis CEO and key strategist 1999 to 2008 Under Wessman‘s leadership Actavis became a leading force in the generic pharmaceutical industry. He changed the company from a small local industry player to the 4th largest global generic company operating in 55 countries.

Alvogen Executive Chairman and CEO 2009-currently As founder and CEO, Wessman has led Alvogen from being a small US based contract manufacturing business to becoming a top 15 global generics player operating in 35 countries in only six years.

Alvogen has received multiple industry recognitions including CPhI Company of the Year Awards and multiple service awards. Development of a balanced yet specialized portfolio consisting of 500 marketed products, as well as a deep pipeline of high-value products in development, is at the core of Wessman’s strategy enabling Alvogen to proactively respond to market needs and fuel sustainable and profitable growth.

Alvotech Founder and Chairman Alvotech is Biopharmaceutical Company with fully integrated R&D, API and fill and finish capabilities with a brand new state-of-the art facilities. Alvotech has 7 biosimilars in the pipeline with the first product launches scheduled in 2019 at patent expiry.

Operational experience and record growth Companies led by Wessman have a collective CAGR of more than 60 percent. He has led over 50 strategic acquisitions and partnerships and established operations in over 60 countries around the globe. These companies have achieved very strong organic growth in combination with external growth.

Wessman’s achievements have made him the subject of two Harvard Business School Case Studies, titled “Robert Wessman and the Actavis Winning Formula” (2008) and “Alvogen” (2015).

Robert Wessman

Arni Hardarson is a director on Alvogen’s Board of Directors and serves as Deputy to the CEO.

Prior to joining Alvogen in 2009, Hardarson worked for Deloitte in Iceland where he headed the Tax and Legal departments and soon went on to become a partner and member of the Executive Management Committee for Deloitte in 2001.

In 2005 Hardarson joined Actavis as Vice President of Tax and Structure. During his tenure there, he worked closely with Robert Wessman and contributed to Actavis’ transformation from a regional manufacturer into a global pharmaceutical company, by engineering numerous company acquisitions that ultimately led to Actavis’ presence in over 40 countries around the world.

Arni Hardarson holds a Master’s degree in Law from the University of Iceland and is a member of the Icelandic Bar Association.

Arni Hardarson

Lisa Graver is the President for the Americas region. Lisa, who joined Alvogen in 2010, has served as EVP of Strategic Operations in the U.S. market for the last three years. In this role she has overseen global R&D and regulatory affairs, portfolio selection, and legal for the U.S.  Under her leadership, Alvogen has built a pipeline 28 potential first-to-file/first-to-market drugs for the U.S. market and a total pipeline of over 60 ANDA‘s. 

Prior to joining Alvogen, Lisa served as Vice President of Intellectual Property for Actavis. She received her JD, cum laude, from Case Western University and Honors Bachelor of Science degree from Lakehead University.

Lisa Graver

Is the Executive Vice President of Asia Pacific. He joined Alvogen in December 2009, after nine years with the generic pharmaceuticals company Actavis Group in various roles – Sales Representative, Division Head in Central Marketing and Senior Manager in Global Business Development.

Petar graduated with a medical doctor’s degree from Sofia University of Medicine, in 1999 and has an MBA degree from University of Sofia “Kliment Ohridski” since October 2007.

Petar Vazharov

Faysal Kalmoua is the Executive Vice President of Portfolio at Alvogen. Kalmoua joined Alvogen in 2015, coming from Synthon, where he worked for nearly sixteen years.  Originally a medicinal chemist, his many qualifications include a Masters Degree in Chemistry (M.Sc.) and an Executive MBA from Insead. 

He has significant strategic and operational experience in senior leadership roles. He has started off in the business working first as a Project Manager for multiple key products and subsequently as head of Business Development, Project Management and Portfolio Management. Since 2010, his main focus has been on "complex" generics, including first to file/ first to market opportunities and paths to differentiate from competitors with a broad coverage of geographies including regulated and semi-regulated markets across the globe.

Faysal Kalmoua

Thor Kristjansson is Alvogen´s EVP for Mergers and Acquisitions. Thor has for over 25 years experience through various positions, specializing on finance, project management and general management.

He leads Alvogen´s global M&A activities with special focus on emerging markets areas in Asia and CEE. Thor further serves as a Board Member of Alvogen´s public companies in Asia, Kunwha and Lotus Pharmaceuticals and will continue to support their growth.

Thor Kristjansson worked for Actavis from 2001 through 2004 as the group´s Deputy CEO, focusing on external growth. Prior to joining Alvogen he worked for several private equity companies and funds focusing on different sectors, including pharmaceuticals, financial services, shipping and seafood.

Thor has served as a board member for several Icelandic and International companies. Thor graduated from University of Iceland in 1988 specializing on Business Administration and Finance.

Thor Kristjansson

Edin Buljubasic was appointed as Alvogen’s General Counsel in June 2019. 

Edin brings 18 years of industry experience from various leadership roles as well as an attorney at law with Wolf Theiss. He joined Alvogen in 2012 and in 2015 he moved to Malta to serve as head of legal for the CEE region.

As General Counsel, Edin’s main focus is on providing advice to Alvogen’s Board and member of the Executive team, making sure that there is an appropriate Legal function and resource in place to meet Alvogen’s business needs, managing that resource, reviewing and establishing group legal policies, and providing advice on key commercial agreements.

Edin Buljubasic

Alvogen’s leadership team is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of our customers. Our organizational structure is lean and flexible, driving quick and effective decision making and thus enabling the company to bring new generic products quickly and safely to market. The executive leadership team forms the Alvogen Management Board.

Meet our management